Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	99.65	141.21	106.14	101.42	112.51
Depreciation & Amortization	1.15	0.8	1.04	1.26	1.48
Stock-Based Compensation	84.5	61.35	48.94	42.44	42.93
Other Adjustments	-41.9	-50.59	-37.3	-30.34	11.43
Change in Receivables	-5.81	-12.85	-10.07	-3.43	-1.43
Changes in Inventories	-7.48	0.31	1.27	1.2	3.44
Changes in Accounts Payable	25.07	-2.02	5.42	4.76	-3.6
Changes in Accrued Expenses	4.01	50.78	24.41	5.06	5.22
Changes in Income Taxes Payable	1.09	3.78	1.21	8.69	0.01
Changes in Other Operating Activities	-18.29	5.54	-14.38	-10.73	-4.11
Operating Cash Flow	142	198.3	126.68	120.32	167.89
Operating Cash Flow Growth	-28.39%	56.53%	5.28%	-28.33%	10.48%
Capital Expenditures	-0.21	-2.17	-0.14	-0.41	-0.47
Purchases of Investments	-319.61	-588.31	-328.75	-355.07	-312.81
Proceeds from Sale of Investments	389.58	412.88	419.79	241.15	449.4
Investing Cash Flow	69.76	-177.6	90.91	-114.33	136.13
Issuance of Common Stock	25.49	9.62	5.81	4.38	16.23
Repurchase of Common Stock	-245.86	-37.97	-154.53	-21.67	-318.82
Net Common Stock Issued (Repurchased)	-220.37	-28.35	-148.72	-17.28	-302.59
Financing Cash Flow	-220.37	-28.35	-148.72	-17.28	-302.59
Effect of Exchange Rate Changes on Cash and Cash Equivalents	1.44	-0.23	0.36	-	-
Net Cash Flow	-7.17	-7.89	69.22	-11.29	1.43
Free Cash Flow	141.79	196.12	126.54	119.91	167.42
Free Cash Flow Growth	-27.71%	54.99%	5.53%	-28.38%	11.07%
FCF Margin	18.62%	29.05%	26.23%	29.84%	45.75%
Free Cash Flow Per Share	1.18	1.73	1.13	1.03	1.33
Levered Free Cash Flow	103.51	196.73	124.33	111.11	114.49
Unlevered Free Cash Flow	72.51	176.75	110.25	108.13	114.01

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q